387 related articles for article (PubMed ID: 25429058)
1. Genetically corrected iPSCs as cell therapy for recessive dystrophic epidermolysis bullosa.
Wenzel D; Bayerl J; Nyström A; Bruckner-Tuderman L; Meixner A; Penninger JM
Sci Transl Med; 2014 Nov; 6(264):264ra165. PubMed ID: 25429058
[TBL] [Abstract][Full Text] [Related]
2. Gene-Corrected Fibroblast Therapy for Recessive Dystrophic Epidermolysis Bullosa using a Self-Inactivating COL7A1 Retroviral Vector.
Jacków J; Titeux M; Portier S; Charbonnier S; Ganier C; Gaucher S; Hovnanian A
J Invest Dermatol; 2016 Jul; 136(7):1346-1354. PubMed ID: 26994967
[TBL] [Abstract][Full Text] [Related]
3. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa.
Chen M; Kasahara N; Keene DR; Chan L; Hoeffler WK; Finlay D; Barcova M; Cannon PM; Mazurek C; Woodley DT
Nat Genet; 2002 Dec; 32(4):670-5. PubMed ID: 12426566
[TBL] [Abstract][Full Text] [Related]
4. Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone.
Woodley DT; Krueger GG; Jorgensen CM; Fairley JA; Atha T; Huang Y; Chan L; Keene DR; Chen M
J Invest Dermatol; 2003 Nov; 121(5):1021-8. PubMed ID: 14708601
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy: pursuing restoration of dermal adhesion in recessive dystrophic epidermolysis bullosa.
Cutlar L; Greiser U; Wang W
Exp Dermatol; 2014 Jan; 23(1):1-6. PubMed ID: 24107073
[TBL] [Abstract][Full Text] [Related]
6. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
[TBL] [Abstract][Full Text] [Related]
7. Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa.
Sebastiano V; Zhen HH; Haddad B; Bashkirova E; Melo SP; Wang P; Leung TL; Siprashvili Z; Tichy A; Li J; Ameen M; Hawkins J; Lee S; Li L; Schwertschkow A; Bauer G; Lisowski L; Kay MA; Kim SK; Lane AT; Wernig M; Oro AE
Sci Transl Med; 2014 Nov; 6(264):264ra163. PubMed ID: 25429056
[TBL] [Abstract][Full Text] [Related]
8. Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa.
Gache Y; Baldeschi C; Del Rio M; Gagnoux-Palacios L; Larcher F; Lacour JP; Meneguzzi G
Hum Gene Ther; 2004 Oct; 15(10):921-33. PubMed ID: 15585108
[TBL] [Abstract][Full Text] [Related]
9. The development of induced pluripotent stem cell-derived mesenchymal stem/stromal cells from normal human and RDEB epidermal keratinocytes.
Nakayama C; Fujita Y; Matsumura W; Ujiie I; Takashima S; Shinkuma S; Nomura T; Abe R; Shimizu H
J Dermatol Sci; 2018 Sep; 91(3):301-310. PubMed ID: 29933899
[TBL] [Abstract][Full Text] [Related]
10. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa.
Wong T; Gammon L; Liu L; Mellerio JE; Dopping-Hepenstal PJ; Pacy J; Elia G; Jeffery R; Leigh IM; Navsaria H; McGrath JA
J Invest Dermatol; 2008 Sep; 128(9):2179-89. PubMed ID: 18385758
[TBL] [Abstract][Full Text] [Related]
11. Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs.
Osborn MJ; Newby GA; McElroy AN; Knipping F; Nielsen SC; Riddle MJ; Xia L; Chen W; Eide CR; Webber BR; Wandall HH; Dabelsteen S; Blazar BR; Liu DR; Tolar J
J Invest Dermatol; 2020 Feb; 140(2):338-347.e5. PubMed ID: 31437443
[TBL] [Abstract][Full Text] [Related]
12. Highly Efficient Ex Vivo Correction of COL7A1 through Ribonucleoprotein-Based CRISPR/Cas9 and Homology-Directed Repair to Treat Recessive Dystrophic Epidermolysis Bullosa.
Berthault C; Gaucher S; Gouin O; Schmitt A; Chen M; Woodley D; Titeux M; Hovnanian A; Izmiryan A
J Invest Dermatol; 2024 Jun; 144(6):1322-1333.e13. PubMed ID: 38043638
[TBL] [Abstract][Full Text] [Related]
13. Gentamicin induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients.
Woodley DT; Cogan J; Hou Y; Lyu C; Marinkovich MP; Keene D; Chen M
J Clin Invest; 2017 Aug; 127(8):3028-3038. PubMed ID: 28691931
[TBL] [Abstract][Full Text] [Related]
14. Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa.
Tolar J; Xia L; Riddle MJ; Lees CJ; Eide CR; McElmurry RT; Titeux M; Osborn MJ; Lund TC; Hovnanian A; Wagner JE; Blazar BR
J Invest Dermatol; 2011 Apr; 131(4):848-56. PubMed ID: 21124339
[TBL] [Abstract][Full Text] [Related]
15. Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa.
Twaroski K; Eide C; Riddle MJ; Xia L; Lees CJ; Chen W; Mathews W; Keene DR; McGrath JA; Tolar J
Br J Dermatol; 2019 Dec; 181(6):1247-1253. PubMed ID: 30924923
[TBL] [Abstract][Full Text] [Related]
16. Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa.
Siprashvili Z; Nguyen NT; Gorell ES; Loutit K; Khuu P; Furukawa LK; Lorenz HP; Leung TH; Keene DR; Rieger KE; Khavari P; Lane AT; Tang JY; Marinkovich MP
JAMA; 2016 Nov; 316(17):1808-1817. PubMed ID: 27802546
[TBL] [Abstract][Full Text] [Related]
17. Keratinocyte cell lines derived from severe generalized recessive epidermolysis bullosa patients carrying a highly recurrent COL7A1 homozygous mutation: models to assess cell and gene therapies in vitro and in vivo.
Chamorro C; Almarza D; Duarte B; Llames SG; Murillas R; García M; Cigudosa JC; Espinosa-Hevia L; Escámez MJ; Mencía A; Meana A; García-Escudero R; Moro R; Conti CJ; Del Río M; Larcher F
Exp Dermatol; 2013 Sep; 22(9):601-3. PubMed ID: 23947675
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa.
Hong SA; Kim SE; Lee AY; Hwang GH; Kim JH; Iwata H; Kim SC; Bae S; Lee SE
Mol Ther; 2022 Aug; 30(8):2664-2679. PubMed ID: 35690907
[TBL] [Abstract][Full Text] [Related]
19. Correction of Recessive Dystrophic Epidermolysis Bullosa by Transposon-Mediated Integration of COL7A1 in Transplantable Patient-Derived Primary Keratinocytes.
Latella MC; Cocchiarella F; De Rosa L; Turchiano G; Gonçalves MAFV; Larcher F; De Luca M; Recchia A
J Invest Dermatol; 2017 Apr; 137(4):836-844. PubMed ID: 28027893
[TBL] [Abstract][Full Text] [Related]
20. Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue.
Ortiz-Urda S; Lin Q; Green CL; Keene DR; Marinkovich MP; Khavari PA
J Clin Invest; 2003 Jan; 111(2):251-5. PubMed ID: 12531881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
